A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine

Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Us...

Full description

Bibliographic Details
Main Authors: Satish K. Dhingra, Devasha Redhi, Jill M. Combrinck, Tomas Yeo, John Okombo, Philipp P. Henrich, Annie N. Cowell, Purva Gupta, Matthew L. Stegman, Jonathan M. Hoke, Roland A. Cooper, Elizabeth Winzeler, Sachel Mok, Timothy J. Egan, David A. Fidock, Thomas E. Wellems
Format: Article
Language:English
Published: American Society for Microbiology 2017-05-01
Series:mBio
Online Access:http://mbio.asm.org/cgi/content/full/8/3/e00303-17
id doaj-141528680c524d41a85c83672164db34
record_format Article
spelling doaj-141528680c524d41a85c83672164db342021-07-02T01:26:35ZengAmerican Society for MicrobiologymBio2150-75112017-05-0183e00303-1710.1128/mBio.00303-17A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug PiperaquineSatish K. DhingraDevasha RedhiJill M. CombrinckTomas YeoJohn OkomboPhilipp P. HenrichAnnie N. CowellPurva GuptaMatthew L. StegmanJonathan M. HokeRoland A. CooperElizabeth WinzelerSachel MokTimothy J. EganDavid A. FidockThomas E. WellemsCurrent efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Using zinc finger nuclease-based gene editing, we report that addition of the C101F mutation to the chloroquine (CQ) resistance-conferring PfCRT Dd2 isoform common to Asia can confer PPQ resistance to cultured parasites. Resistance was demonstrated as significantly higher PPQ concentrations causing 90% inhibition of parasite growth (IC90) or 50% parasite killing (50% lethal dose [LD50]). This mutation also reversed Dd2-mediated CQ resistance, sensitized parasites to amodiaquine, quinine, and artemisinin, and conferred amantadine and blasticidin resistance. Using heme fractionation assays, we demonstrate that PPQ causes a buildup of reactive free heme and inhibits the formation of chemically inert hemozoin crystals. Our data evoke inhibition of heme detoxification in the parasite’s acidic digestive vacuole as the primary mode of both the bis-aminoquinoline PPQ and the related 4-aminoquinoline CQ. Both drugs also inhibit hemoglobin proteolysis at elevated concentrations, suggesting an additional mode of action. Isogenic lines differing in their pfmdr1 copy number showed equivalent PPQ susceptibilities. We propose that mutations in PfCRT could contribute to a multifactorial basis of PPQ resistance in field isolates.http://mbio.asm.org/cgi/content/full/8/3/e00303-17
collection DOAJ
language English
format Article
sources DOAJ
author Satish K. Dhingra
Devasha Redhi
Jill M. Combrinck
Tomas Yeo
John Okombo
Philipp P. Henrich
Annie N. Cowell
Purva Gupta
Matthew L. Stegman
Jonathan M. Hoke
Roland A. Cooper
Elizabeth Winzeler
Sachel Mok
Timothy J. Egan
David A. Fidock
Thomas E. Wellems
spellingShingle Satish K. Dhingra
Devasha Redhi
Jill M. Combrinck
Tomas Yeo
John Okombo
Philipp P. Henrich
Annie N. Cowell
Purva Gupta
Matthew L. Stegman
Jonathan M. Hoke
Roland A. Cooper
Elizabeth Winzeler
Sachel Mok
Timothy J. Egan
David A. Fidock
Thomas E. Wellems
A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
mBio
author_facet Satish K. Dhingra
Devasha Redhi
Jill M. Combrinck
Tomas Yeo
John Okombo
Philipp P. Henrich
Annie N. Cowell
Purva Gupta
Matthew L. Stegman
Jonathan M. Hoke
Roland A. Cooper
Elizabeth Winzeler
Sachel Mok
Timothy J. Egan
David A. Fidock
Thomas E. Wellems
author_sort Satish K. Dhingra
title A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
title_short A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
title_full A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
title_fullStr A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
title_full_unstemmed A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine
title_sort variant pfcrt isoform can contribute to plasmodium falciparum resistance to the first-line partner drug piperaquine
publisher American Society for Microbiology
series mBio
issn 2150-7511
publishDate 2017-05-01
description Current efforts to reduce the global burden of malaria are threatened by the rapid spread throughout Asia of Plasmodium falciparum resistance to artemisinin-based combination therapies, which includes increasing rates of clinical failure with dihydroartemisinin plus piperaquine (PPQ) in Cambodia. Using zinc finger nuclease-based gene editing, we report that addition of the C101F mutation to the chloroquine (CQ) resistance-conferring PfCRT Dd2 isoform common to Asia can confer PPQ resistance to cultured parasites. Resistance was demonstrated as significantly higher PPQ concentrations causing 90% inhibition of parasite growth (IC90) or 50% parasite killing (50% lethal dose [LD50]). This mutation also reversed Dd2-mediated CQ resistance, sensitized parasites to amodiaquine, quinine, and artemisinin, and conferred amantadine and blasticidin resistance. Using heme fractionation assays, we demonstrate that PPQ causes a buildup of reactive free heme and inhibits the formation of chemically inert hemozoin crystals. Our data evoke inhibition of heme detoxification in the parasite’s acidic digestive vacuole as the primary mode of both the bis-aminoquinoline PPQ and the related 4-aminoquinoline CQ. Both drugs also inhibit hemoglobin proteolysis at elevated concentrations, suggesting an additional mode of action. Isogenic lines differing in their pfmdr1 copy number showed equivalent PPQ susceptibilities. We propose that mutations in PfCRT could contribute to a multifactorial basis of PPQ resistance in field isolates.
url http://mbio.asm.org/cgi/content/full/8/3/e00303-17
work_keys_str_mv AT satishkdhingra avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT devasharedhi avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT jillmcombrinck avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT tomasyeo avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT johnokombo avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT philippphenrich avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT anniencowell avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT purvagupta avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT matthewlstegman avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT jonathanmhoke avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT rolandacooper avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT elizabethwinzeler avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT sachelmok avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT timothyjegan avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT davidafidock avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT thomasewellems avariantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT satishkdhingra variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT devasharedhi variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT jillmcombrinck variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT tomasyeo variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT johnokombo variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT philippphenrich variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT anniencowell variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT purvagupta variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT matthewlstegman variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT jonathanmhoke variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT rolandacooper variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT elizabethwinzeler variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT sachelmok variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT timothyjegan variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT davidafidock variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
AT thomasewellems variantpfcrtisoformcancontributetoplasmodiumfalciparumresistancetothefirstlinepartnerdrugpiperaquine
_version_ 1721344941039288320